These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 30481388)

  • 1. Omalizumab discontinuation in children with severe allergic asthma: An observational real-life study.
    Deschildre A; Roussel J; Drumez E; Abou-Taam R; Rames C; Le Roux P; Pouessel G; Scalbert M; Bonnel C; Mitha S; Boileau S; Mordacq C; Thumerelle C; Labreuche J; Lejeune S; Marguet C
    Allergy; 2019 May; 74(5):999-1003. PubMed ID: 30481388
    [No Abstract]   [Full Text] [Related]  

  • 2. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.
    Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S
    Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic reaction rates with omalizumab, subcutaneous immunotherapy, and combination therapy in children with allergic asthma.
    Har D; Lee MJ
    Allergy Asthma Proc; 2019 Jan; 40(1):35-40. PubMed ID: 30582494
    [No Abstract]   [Full Text] [Related]  

  • 4. Omalizumab for severe allergic asthma in clinical trials and real-life studies: what we know and what we should address.
    Caminati M; Senna G; Guerriero M; Dama AR; Chieco-Bianchi F; Stefanizzi G; Montagni M; Ridolo E
    Pulm Pharmacol Ther; 2015 Apr; 31():28-35. PubMed ID: 25640019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different Skin Prick Test Sensitization Patterns Do Not Influence the Response to Omalizumab in Severe Asthma.
    Sposato B; Scalese M; Milanese M; Masieri S; Cavaliere C; Latorre M; Scichilone N; Matucci A; Vultaggio A; Ricci A; Cresti A; Paggiaro PL
    J Investig Allergol Clin Immunol; 2017; 27(6):388-391. PubMed ID: 29199967
    [No Abstract]   [Full Text] [Related]  

  • 6. 'Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review.
    Abraham I; Alhossan A; Lee CS; Kutbi H; MacDonald K
    Allergy; 2016 May; 71(5):593-610. PubMed ID: 26644231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review.
    Corren J; Kavati A; Ortiz B; Colby JA; Ruiz K; Maiese BA; Cadarette SM; Panettieri RA
    Allergy Asthma Proc; 2017 Jul; 38(4):250-263. PubMed ID: 28631599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study.
    Domingo C; Pomares X; Navarro A; Rudi N; Sogo A; Dávila I; Mirapeix RM
    Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omalizumab management beyond clinical trials: the added value of a network model.
    Caminati M; Senna G; Chieco Bianchi F; Marchi MR; Vianello A; Micheletto C; Pomari C; Tognella S; Savoia F; Mirisola V; Rossi A;
    Pulm Pharmacol Ther; 2014 Oct; 29(1):74-9. PubMed ID: 24508951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-life long-term omalizumab therapy in children with severe allergic asthma.
    Deschildre A; Marguet C; Langlois C; Pin I; Rittié JL; Derelle J; Abou Taam R; Fayon M; Brouard J; Dubus JC; Siret D; Weiss L; Pouessel G; Beghin L; Just J
    Eur Respir J; 2015 Sep; 46(3):856-9. PubMed ID: 26022964
    [No Abstract]   [Full Text] [Related]  

  • 11. Pediatric use of omalizumab for allergic asthma.
    Pajno GB; Castagnoli R; Arasi S; Licari A; Caminiti L; Marseglia GL
    Expert Opin Biol Ther; 2020 Jul; 20(7):695-703. PubMed ID: 32241196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does omalizumab impair glucose homeostasis in a patient with severe persistent asthma and type 2 diabetes mellitus?
    Hamada S; Kuroe A; Tsukino M
    Rev Port Pneumol (2006); 2017; 23(5):303-304. PubMed ID: 28602732
    [No Abstract]   [Full Text] [Related]  

  • 13. Changes in asthma control, work productivity, and impairment with omalizumab: 5-year EXCELS study results.
    Zazzali JL; Raimundo KP; Trzaskoma B; Rosén KE; Schatz M
    Allergy Asthma Proc; 2015; 36(4):283-92. PubMed ID: 26108086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Omalizumab in children with uncontrolled asthma: a real-life study carried out in Colombia].
    Morales-Múnera O; Pedraza Á; Niño-Serna L
    Rev Alerg Mex; 2018; 65(3):222-232. PubMed ID: 30176200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma.
    Nieto García A; Garriga-Baraut T; Plaza Martín AM; Nieto Cid M; Torres Borrego J; Folqué Giménez MDM; Lozano Blasco J; Bosque García M; Moreno-Galarraga L; Tortajada-Girbés M; Rivas Juesas C; Penín Antón M; Caballero-Rabasco MA; Gaboli M; López Neyra A; Navarro Morón J; Freixa Benavente A; Valdesoiro Navarrete L; Ballester Asensio E; Sanz Santiago V; Romero García R; Gimeno Díaz de Atauri Á; Valenzuela Soria A; Sánchez Mateos M; Batlles Garrido J; Andrés Martín A; Campos Alonso E; Aragón Fernández C; Vázquez Rodríguez E; Martínez Pardo L; Del-Río Camacho G; Mazón Ramos Á
    Pediatr Allergy Immunol; 2021 Jul; 32(5):980-991. PubMed ID: 33619748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab as a Therapeutic Option for Nasal Polyposis in Moderate-to-Severe Persistent Allergic Asthma: Evidence From a Prospective Study in a Real-World Setting.
    Ruiz-Hornillos J; Rodríguez Jiménez B; Feliu Vila A; Moreno Fernández A; Hernández García MJ; Domínguez-Ortega J;
    J Investig Allergol Clin Immunol; 2020; 30(6):470-472. PubMed ID: 32490823
    [No Abstract]   [Full Text] [Related]  

  • 17. Asthma control in severe asthmatics under treatment with omalizumab: a cross-sectional observational study in Italy.
    Novelli F; Latorre M; Vergura L; Caiaffa MF; Camiciottoli G; Guarnieri G; Matucci A; Macchia L; Vianello A; Vultaggio A; Celi A; Cazzola M; Paggiaro P;
    Pulm Pharmacol Ther; 2015 Apr; 31():123-9. PubMed ID: 25281265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between allergen immunotherapy and omalizumab for treating asthma.
    Braido F; Corsico A; Rogkakou A; Ronzoni V; Baiardini I; Canonica GW
    Expert Rev Respir Med; 2015 Apr; 9(2):129-34. PubMed ID: 25578528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity influences the outcomes of anti-IgE (omalizumab) therapy of asthma.
    Gu C; Upchurch K; Mamaril-Davis J; Wiest M; Lanier B; Millard M; Turner J; Joo H; Oh S
    Clin Exp Allergy; 2020 Oct; 50(10):1196-1199. PubMed ID: 32585057
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study.
    Di Bona D; Fiorino I; Taurino M; Frisenda F; Minenna E; Pasculli C; Kourtis G; Rucco AS; Nico A; Albanesi M; Giliberti L; D'Elia L; Caiaffa MF; Macchia L
    Respir Med; 2017 Sep; 130():55-60. PubMed ID: 29206634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.